JNJ Q3 2026 Earnings Analysis
Johnson & Johnson reported Q3 revenue of $25.4B with 6% operational growth and raised full-year guidance, driven by Innovative Medicine strength while managing MedTech headwinds outside the U.S.
Key Metrics
Points clés
- J&J posted Q3 revenue of $25.4B with 6% operational growth, on track to exceed $100B annual revenue for the first time.
- Innovative Medicine drove performance with 7.9% growth; oncology up ~17% led by RYBREVANT and multiple myeloma strength.
- MedTech grew only 2.5%; management targeting improvements in cardiovascular and surgery, especially outside the U.S.
Écouter sur
Disponible en
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're diving into Johnson & Johnson's third quarter 2026 results, reported Tuesday. Before we get going, a quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
And there's a lot to unpack here, Alex, because on the surface this looks like a messy quarter, but underneath it's actually a pretty strong one.
Right, let's start with the headline numbers. J&J posted $25.4 billion in revenue for Q3, up 6% operationally, which actually beat analyst expectations. Management raised full-year guidance and now expects full-year operational sales growth of 6.7% to 7.1%, putting them on track to cross $100 billion in annual revenue for the very first time in the company's 140-year history.
That's a huge milestone. But here's where it gets messy — GAAP net earnings were just $210 million, and diluted EPS came in at nine cents, compared to $2.12 a year ago. That's a massive drop.
And the reason is a one-time hit, not a business problem. J&J took a $5.5 billion charge tied to resolving the ovarian talc litigation, plus costs from two acquisitions — Firefly Bio in oncology and a collaboration with Cell BioMedicine in cell therapy. Strip those out, and adjusted EPS was $2.59, down about 7.5% year-over-year, but mostly because of those deal-related expenses, not underlying weakness.
Exactly. The core business is actually accelerating. Innovative Medicine — that's their pharma segment — grew 7.9% operationally to $16.8 billion, with eight brands growing double digits. Oncology alone grew 17%.
Let's talk about the stars of the show. Tremfya, their immunology drug, grew 68% in the quarter. CARVYKTI, their multiple myeloma cell therapy, up 35%. And RYBREVANT, for lung cancer, up 64%. Tom Cavanaugh, the head of Innovative Medicine, specifically called out Icotrokinra — their new oral psoriasis treatment — saying it's tracking better than almost any launch they've seen in psoriatic disease, with over 20,000 patients started in just months.
What stood out to me is they're calling this a path to double-digit growth by 2030, and when an analyst from Goldman pressed CFO Joe Wolk on whether that assumes big acquisitions, he was pretty direct — no, it's organic. That's a meaningful claim given how reliant a lot of pharma growth stories are on M&A.
Now, MedTech is the other side of the story, and it's where things got rockier. That division only grew 2.5%, missing expectations. Management was candid about it — Timothy Schmid, who runs MedTech, basically said "our performance is below the standard we set internally."
Two specific problem areas: international markets, especially due to disruption from the Middle East conflict affecting hospital purchasing and tender timing, and Abiomed, their heart pump business, which actually declined 1.5% because of a disputed study on high-risk PCI procedures. Execs pushed back hard on that study's methodology.
But it wasn't all bad news in MedTech. Shockwave, their cardiovascular device business, grew 17%. And they got FDA clearance for Ottava, their new surgical robot — first commercial customer already signed. That's a big long-term bet on competing with Intuitive Surgical in robotics.
One housekeeping item investors should note — J&J confirmed they're still on track to spin off their orthopedics business, DePuy Synthes, by mid-2027, and they're leaning toward a straight spin-off rather than a sale.
Let's hit a couple of Q&A highlights. On Icotrokinra, management wouldn't disclose exact sales yet but said they'll start breaking it out next year given the momentum. And on Inlexzo, their bladder cancer therapy, they revealed it did north of $90 million in the quarter alone, with new patient starts up 45% sequentially — pretty remarkable for a product just over a year into launch.
And looking ahead to 2027, Joe Wolk gave some early framework — expect reported sales growth similar to 2026 after adjusting for an extra week in the calendar, and note that the Firefly Bio and Cell BioMedicine deals will create a $1.36 per share drag on earnings next year. They'll lay out more detail at their Investor Day on December 8th.
So what's the takeaway for listeners? The pharma side of J&J is firing on all cylinders — oncology, immunology, and neuroscience are genuinely strong growth engines, and new launches like Icotrokinra and Inlexzo are tracking ahead of plan. MedTech needs fixing, and management knows it, pointing to fixable, mostly geography-specific issues rather than structural decline.
And the GAAP earnings headline looks scary, but it's really a one-time litigation settlement and deal costs, not a sign the business is struggling. That December 8th Investor Day is shaping up to be the next real catalyst to watch, since that's when they'll lay out the 2027 outlook and more color on Ottava's growth potential.
Before we wrap up — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Couldn't have said it better myself. J&J looks like a company in transition — leaning hard into its highest-growth areas while working through some near-term bumps in MedTech. We'll be watching closely as they head toward that $100 billion milestone and the December investor update.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time as we break down another earnings call.
See you then.